Corcept Therapeutics Incorporated - Laporan Laba Rugi (TTM)

Corcept Therapeutics Incorporated
US ˙ NasdaqCM ˙ US2183521028

Laporan Laba Rugi (TTM)

Laporan Laba Rugi Corcept Therapeutics Incorporated menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 356 354 340 343 353 366 380 392 398 402 414 428 450 482 524 570 629 675 685 716
Change (%) -0.61 -3.90 0.89 2.86 3.71 3.89 3.10 1.43 1.06 2.98 3.46 5.11 7.19 8.53 8.80 10.35 7.40 1.54 4.47
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 6 6 5 5 5 5 5 5 5 5 6 6 6 6 7 8 9 11 11 12
Change (%) -3.16 -10.93 3.02 1.15 1.93 -0.34 -1.29 1.23 2.40 2.53 4.67 5.28 6.53 10.01 13.32 15.14 16.97 3.38 8.08
% of Revenue 1.62 1.58 1.46 1.49 1.47 1.44 1.38 1.33 1.32 1.34 1.33 1.35 1.35 1.34 1.36 1.42 1.48 1.61 1.64 1.70
Gross Operating Profit 350 348 335 338 348 361 375 387 392 396 408 422 444 476 516 562 619 664 674 704
Change (%) -0.56 -3.79 0.86 2.88 3.74 3.96 3.16 1.43 1.05 2.98 3.45 5.11 7.20 8.51 8.74 10.28 7.25 1.51 4.41
% of Revenue 98.38 98.42 98.54 98.51 98.53 98.56 98.62 98.67 98.68 98.66 98.67 98.65 98.65 98.66 98.64 98.58 98.52 98.39 98.36 98.30
SG&A 107 105 107 112 116 122 130 138 143 153 164 169 179 184 192 216 244 280 315 352
Change (%) -1.34 1.87 4.15 3.59 5.69 6.57 5.97 3.35 7.03 7.21 3.34 5.96 2.69 4.18 12.32 13.21 14.84 12.27 11.73
% of Revenue 29.99 29.76 31.55 32.57 32.81 33.43 34.29 35.25 35.92 38.04 39.60 39.55 39.87 38.20 36.67 37.85 38.84 41.53 45.91 49.10
R&D 111 115 118 119 114 114 113 118 123 131 144 154 166 184 202 217 231 247 249 251
Change (%) 3.58 2.53 1.47 -4.84 0.21 -0.79 4.07 4.42 6.71 9.72 7.27 7.93 10.79 9.58 7.66 6.35 6.74 0.90 0.69
% of Revenue 31.12 32.43 34.60 34.80 32.20 31.11 29.71 29.99 30.87 32.60 34.73 36.01 36.98 38.22 38.59 38.18 36.80 36.57 36.34 35.03
OpEx 223 226 230 236 235 242 249 261 271 289 313 329 352 375 401 441 485 538 575 615
Change (%) 1.05 1.89 2.76 -0.72 2.96 2.95 4.95 3.79 6.79 8.26 5.17 6.87 6.59 6.93 9.99 9.87 11.02 6.87 6.88
% of Revenue 62.73 63.77 67.62 68.87 66.47 65.99 65.39 66.56 68.11 71.97 75.66 76.91 78.20 77.76 76.61 77.45 77.11 79.71 83.90 85.83
Operating Income 133 128 110 107 118 124 132 131 127 113 101 99 98 107 122 128 144 137 110 101
Change (%) -3.40 -14.10 -3.01 10.78 5.20 5.73 -0.39 -3.28 -11.17 -10.58 -1.84 -0.77 9.35 14.12 4.91 12.01 -4.80 -19.41 -8.08
% of Revenue 37.27 36.23 32.38 31.13 33.53 34.01 34.61 33.44 31.89 28.03 24.34 23.09 21.80 22.24 23.39 22.55 22.89 20.29 16.10 14.17
Interest Expense
Change (%)
% of Revenue
Net Income 109 106 99 98 106 113 112 113 117 101 94 95 91 106 118 126 142 141 134 134
Change (%) -3.10 -6.23 -1.81 9.06 5.69 -0.59 0.79 3.67 -13.22 -6.82 0.12 -3.41 16.14 11.20 6.74 12.57 -0.43 -5.11 -0.25
% of Revenue 30.73 29.96 29.23 28.45 30.17 30.74 29.41 28.76 29.39 25.24 22.84 22.10 20.31 22.00 22.54 22.12 22.56 20.92 19.55 18.66

Source: Capital IQ

Other Listings
IT:1CORT € 61.62
GB:0I3Q
DE:HTD € 58.86
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista